Exelixis: Neoplasms trials

The registry lists 11 Neoplasms studies with Exelixis as lead sponsor. 2 are open to participants now and 2 have results posted.

Phase 1 8Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNot yet recruitingNCT07773454Phase 1
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3
• Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT03937219Phase 3Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingNCT03755791Phase 3Results posted
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)TerminatedNCT04726332Phase 1
• A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsActive, not recruitingNCT03845166Phase 1
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
• Study of XL228 Administered Intravenously to Subjects With Advanced MalignanciesTerminatedNCT00526838Phase 1
• A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced MalignanciesTerminatedNCT00475917Phase 1
• Study of XL418 in Adults With Solid TumorsSuspendedNCT00460278Phase 1
• Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesCompletedNCT00215605Phase 1